Drug intelligence / Profile preview

K6

Development stage: Preclinical
Lead developer: HighField Biopharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

K6 is a preclinical-stage bispecific antibody-drug conjugate (ADC) being developed by HighField Biopharmaceuticals for the treatment of autoimmune diseases. As a bispecific ADC, it is designed to target two distinct antigens or epitopes, potentially enhancing specificity and efficacy in modulating immune responses compared to monospecific agents. While specific targets and the nature of the payload have not been publicly disclosed, the asset represents HighField's expansion of its ADC platform into non-oncology indications.

Beyond the preview

Go deeper on K6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K6.

Explore the full profile